The 12-node rule in irradiated rectal cancer: time for reappraisal?

For more than two decades, the recommendation to examine a minimum of 12 lymph nodes in colorectal cancer specimens has been incorporated into staging systems. This benchmark, largely derived from surgery-first colon cancer cohorts, was intended to improve prognostication and reduce under staging (1,2). Over time, the 12-lymph-node-rule came to represent not only staging adequacy but also surgical and pathological quality and was extrapolated to rectal cancer alongside the rise of neoadjuvant therapy (3,4). Given neoadjuvant chemoradiotherapy (NCRT) followed by total mesorectal excision (TME) is currently established as standard care for locally advanced rectal cancer (4,5), it is reasonable to question the appropriateness of a historic nodal threshold determined during the pre-neoadjuvant era of colorectal cancer management.

In the December 2025 issue of the Journal of Gastrointestinal Oncology, Xi et al. analyse 6,634 patients treated with long-course NCRT followed by radical resection, evaluating the prognostic significance of examined lymph node (ELN) count (6). Across both an institutional cohort and a Surveillance, Epidemiology, and End Results (SEER) validation cohort, the traditional 12-node threshold failed to demonstrate meaningful survival outcomes. Using outcome-based X-tile analysis, the authors propose seven nodes as a more appropriate minimum threshold in this setting, with ELN <7 independently associated with inferior disease-free survival (DFS) and cancer-specific survival. Their findings contribute to an ongoing discussion regarding the interpretation of lymph node yield in irradiated rectal specimens.

The reduction in nodal yield following neoadjuvant therapy is well described. Population-based studies and systematic reviews consistently demonstrate fewer lymph nodes retrieved after preoperative radiation compared with surgery alone (7-11). In a meta-analysis of rectal resections following neoadjuvant therapy, Mechera et al. reported a significant reduction in ELN relative to non-irradiated cohorts by average of 2.1 nodes (9). Similar findings have been reproduced across large institutional and registry-based studies (7,8,10). Importantly, this reduction occurs despite adherence to TME principles, suggesting that the phenomenon is not exclusively attributable to operative technique.

Radiation-induced changes within the mesorectum provide a biological explanation for reduced nodal yield after NCRT. Histopathological studies have described lymphoid atrophy, stromal fibrosis, architectural distortion, and nodal regression within irradiated specimens (8,12-14). Mekenkamp et al. demonstrated that NCRT independently reduces lymph node retrieval after adjusting for tumour and patient-related factors, noting that irradiated nodes are often smaller and may fall below the threshold of pathological detection (12). These structural alterations provide a plausible mechanical basis for reduced nodal harvest in treated specimens.

Beyond these structural effects, NCRT also alters the biological status of regional nodes. Downstaging to ypN0 after NCRT is associated with improved outcomes compared with persistent nodal disease, and in this setting the prognostic impact of ELN count appears reduced (11,15). Thus, in rectal cancer, ELN quantity, in those who have undergone neoadjuvant therapy, may not correspond to residual tumour burden in the same way as in surgery-first disease.

Tumour regression grade (TRG) provides further insight. Several studies have established TRG as a robust predictor of DFS and overall survival (OS) following preoperative therapy (16,17). Deeper tumour regression frequently parallels nodal downstaging, and favourable TRG is associated with reduced residual nodal metastasis (16). Specimens demonstrating marked regression may therefore exhibit both diminished nodal involvement and reduced nodal detectability. Therefore, ELN after NCRT may reflect treatment response intensity more than surgical diligence.

Lymph node ratio (LNR), defined as the proportion of positive nodes to ELN, may offer complementary prognostic information that is less dependent on ELN alone. Elevated LNR has been associated with inferior survival in incidental node-positive rectal cancer (18). In stage III colorectal cancer, 5-year OS declines from 73.8% when LNR is ≤0.10% to 40.6% when it exceeds 0.16, outperforming conventional node (N) staging (19), with its independent prognostic value confirmed in systematic analyses (20).

As stated earlier, one of the original justifications for examining at least 12 lymph nodes was to minimise under staging. In colon cancer, evaluating fewer nodes increases the risk of missing nodal metastases and resulting in inadvertent stage migration and potential omission of appropriate adjuvant therapy. This reasoning is grounded in the “Will Rogers phenomenon”, whereby more accurate staging improves apparent survival through reclassification (21). However, applying this principle to rectal cancer treated with NCRT is less straightforward as nodal downstaging is common, thereby changing the implications of retrieving fewer than 12 nodes from those who had surgery first in colon cancer.

Xi et al.’s proposal of seven nodes as an optimal minimum therefore warrants careful interpretation (6). The cutoff was derived using an outcome-based minimum P value approach with X-tile, a method that can identify statistically significant inflection points within a given dataset but may be sensitive to cohort-specific effects (22). While the consistency across institutional and population-based cohorts strengthens the signal, key pathological variables, such as TRG, extramural vascular invasion (EMVI), and circumferential resection margin (CRM) status, including TME integrity as defined by the Quirke classification, were unavailable in SEER. These factors limit definitive conclusions regarding biological versus technical drivers of nodal yield. Nevertheless, the authors should be commended for interrogating a long-standing staging metric within an NCRT treated population and for validating their findings across independent datasets.

Taken together, ELN following NCRT should be interpreted in context rather than judged against an absolute number. Unusually low counts such as fewer than three or four nodes, warrant scrutiny of operative completeness and pathological assessments. Yet as we established, moderate reductions in ELN are frequently a consequence of treatment effect. Among patients rendered ypN0 with good regression and clear margins, the prognostic difference between retrieving seven versus twelve nodes is unlikely to be clinically meaningful.

Rather than replacing one rigid benchmark with another, a contextual and individualised approach may be more appropriate. In irradiated rectal cancer, nodal yield should be interpreted in conjunction with yp stage, TRG, CRM, EMVI, perineural invasion and other adverse pathological features. ELN count may retain relevance at the extremes, particularly when yields are exceptionally low, but it is unlikely to independently determine prognosis once other pathological and treatment-related factors are taken into consideration.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Journal of Gastrointestinal Oncology. The article did not undergo external peer review.

Funding: None.

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-2026-0256/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Compton CC, Greene FL. The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 2004;54:295-308. [Crossref] [PubMed]
2. Parsons HM, Tuttle TM, Kuntz KM, et al. Association between lymph node evaluation for colon cancer and node positivity over the past 20 years. JAMA 2011;306:1089-97. [Crossref] [PubMed]
3. Marks JH, Valsdottir EB, Rather AA, et al. Fewer than 12 lymph nodes can be expected in a surgical specimen after high-dose chemoradiation therapy for rectal cancer. Dis Colon Rectum 2010;53:1023-9. [Crossref] [PubMed]
4. Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2018;16:874-901. [Crossref] [PubMed]
5. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40. [Crossref] [PubMed]
6. Xi K, Feng L, Xu T, et al. The optimal number of lymph nodes examined for rectal cancer patients undergoing neoadjuvant long-course chemoradiotherapy. J Gastrointest Oncol 2025;16:2620-31. [Crossref] [PubMed]
7. Baxter NN, Morris AM, Rothenberger DA, et al. Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis. Int J Radiat Oncol Biol Phys 2005;61:426-31. [Crossref] [PubMed]
8. Amajoyi R, Lee Y, Recio PJ, et al. Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens. Am J Surg 2013;205:289-92; discussion 292. [Crossref] [PubMed]
9. Mechera R, Schuster T, Rosenberg R, et al. Lymph node yield after rectal resection in patients treated with neoadjuvant radiation for rectal cancer: A systematic review and meta-analysis. Eur J Cancer 2017;72:84-94. [Crossref] [PubMed]
10. Ha YH, Jeong SY, Lim SB, et al. Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer. Ann Surg 2010;252:336-40. [Crossref] [PubMed]
11. Bustamante-Lopez LA, Nahas CSR, Nahas SC, et al. Pathologic complete response implies a fewer number of lymph nodes in specimen of rectal cancer patients treated by neoadjuvant therapy and total mesorectal excision. Int J Surg 2018;56:283-7. [Crossref] [PubMed]
12. Mekenkamp LJ, van Krieken JH, Marijnen CA, et al. Lymph node retrieval in rectal cancer is dependent on many factors--the role of the tumor, the patient, the surgeon, the radiotherapist, and the pathologist. Am J Surg Pathol 2009;33:1547-53. [Crossref] [PubMed]
13. Gurawalia J, Dev K, Nayak SP, et al. Less than 12 lymph nodes in the surgical specimen after neoadjuvant chemo-radiotherapy: an indicator of tumor regression in locally advanced rectal cancer? J Gastrointest Oncol 2016;7:946-57. [Crossref] [PubMed]
14. Beresford M, Glynne-Jones R, Richman P, et al. The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol) 2005;17:448-55. [Crossref] [PubMed]
15. Tsai CJ, Crane CH, Skibber JM, et al. Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. Cancer 2011;117:3713-22. [Crossref] [PubMed]
16. Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 2014;32:1554-62. [Crossref] [PubMed]
17. Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-96. [Crossref] [PubMed]
18. Thong DW, Chakraborty P, Rajan R, et al. Adjuvant Radiotherapy in Incidental Positive Nodal Disease in Rectal Cancer-A Systemic Review. J Surg Oncol 2025;132:622-32. [Crossref] [PubMed]
19. Beirat AF, Amarin JZ, Suradi HH, et al. Lymph node ratio is a more robust predictor of overall survival than N stage in stage III colorectal adenocarcinoma. Diagn Pathol 2024;19:44. [Crossref] [PubMed]
20. Ceelen W, Van Nieuwenhove Y, Pattyn P. Prognostic value of the lymph node ratio in stage III colorectal cancer: a systematic review. Ann Surg Oncol 2010;17:2847-55. [Crossref] [PubMed]
21. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-8.
22. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-9. [Crossref] [PubMed]